Châtillon, France, October 6, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company’s At-The-Market program established on September 5, 2025 (the “ATM Program”), it has agreed to issue and sell new ordinary shares (the “Ordinary Shares”) in the form ...

Châtillon, France, October 6, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company’s At-The-Market program established on September 5, 2025 (the “ATM Program”), it has agreed to issue and sell new ordinary shares (the “Ordinary Shares”) in the form ...

Core Viewpoint - DBV Technologies announced the resignation of Daniel Soland from its Board of Directors, effective immediately, and expressed gratitude for his contributions since 2015 [1][2]. Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions with significant unmet medical needs [3]. - The company is investigating its proprietary VIASKIN® patch technology, which aims to address food allergies through epicutaneous immunotherapy (EPIT) [3]. - The VIASKIN® patch is designed to introduce microgram amounts of biologically active compounds to the immune system via intact skin, aiming to modify the underlying allergy and desensitize the immune system [3]. Current Operations - DBV Technologies is conducting ongoing clinical trials of the VIASKIN Peanut patch for peanut allergic toddlers (ages 1 to 3) and children (ages 4 to 7) [3]. - The company is headquartered in Châtillon, France, with North American operations in Warren, NJ [4]. - The ordinary shares of DBV Technologies are traded on segment B of Euronext Paris, and its American Depositary Shares (ADSs) are traded on the Nasdaq Capital Market [4].

Core Viewpoint - DBV Technologies has established an At-The-Market (ATM) program to offer up to $150 million of American Depositary Shares (ADS) on Nasdaq, aimed at financing activities related to its Biologics License Application (BLA) and the development of its proprietary technology platform, VIASKIN [1][2]. Group 1: ATM Program Details - The ATM program allows DBV Technologies to sell ADSs representing five ordinary shares, with sales dependent on various market factors [1]. - The program is intended to remain effective until the maximum gross amount is sold or terminated according to the sales agreement with Citizens JMP Securities, LLC [1]. - The previous ATM program established on May 2, 2022, has been terminated, but the new program's terms are similar [1]. Group 2: Use of Proceeds - The net proceeds from the ATM program will primarily be used for activities associated with the BLA, potential approval and launch of the VIASKIN Peanut patch for toddlers aged 1-3, and advancing the development of other product candidates [2]. Group 3: Sales Agreement and Pricing - Citizens JMP Securities will act as the sales agent, using commercially reasonable efforts to sell the ADSs to eligible investors [3]. - The sales price of the new ordinary shares will not be less than the last closing price or the volume-weighted average price over a specified period, with a maximum discount of 15% [3]. Group 4: Share Capital and Dilution - The issuance of new ordinary shares will occur without preferential subscription rights, with a maximum potential dilution of approximately 50% based on existing share capital [4]. - The number of underlying ordinary shares will not exceed the limit set by the shareholders and will represent less than 30% of the ordinary shares already admitted to trading over a rolling 12-month period [4][8]. Group 5: Investor Eligibility - Purchases of ADSs under the ATM program are limited to specific categories of investors, including those regularly investing in the pharmaceutical, biotechnological, or medical technology sectors [6]. Group 6: Trading Information - The new ordinary shares will be admitted to trading on Euronext in Paris, while the issued ADSs will trade on the Nasdaq Capital Market [7]. Group 7: Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies using its proprietary VIASKIN patch technology [13]. - The company is headquartered in Châtillon, France, with operations in North America [14].

Châtillon, France, September 3, 2025 DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025, at 11:30am ET, in New York, NY. A live web ...

Core Insights - DBV Technologies has filed its 2025 Half-Year Report with the French market authority, AMF, for the period ending June 30, 2025 [1] - The company is focused on developing treatment options for food allergies and other immunologic conditions, utilizing its proprietary VIASKIN patch technology [2][3] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company headquartered in Châtillon, France, with operations in North America [3] - The company is dedicated to addressing significant unmet medical needs related to food allergies, particularly through epicutaneous immunotherapy (EPIT) [2] - The VIASKIN patch aims to desensitize individuals to allergens by introducing microgram amounts of biologically active compounds through intact skin [2] Clinical Focus - DBV Technologies is currently conducting clinical trials for its VIASKIN Peanut product, targeting peanut allergic toddlers aged 1 to 3 years and children aged 4 to 7 years [2]

Core Viewpoint - DBV Technologies reported its financial results for the second quarter and half-year of 2025, highlighting a net loss and changes in operating income and expenses, while also discussing its ongoing development of the Viaskin Peanut patch for food allergies [1][19]. Financial Highlights - The interim condensed consolidated financial statements were prepared in accordance with U.S. GAAP and IFRS [2]. - Operating income for the six months ended June 30, 2025, was $2.2 million, a decrease from $2.6 million in the same period of 2024, primarily due to a lower French Research Tax Credit entitlement [3][4]. - Operating expenses increased to $69.9 million for the six months ended June 30, 2025, compared to $65.0 million for the same period in 2024, driven mainly by the launch of the COMFORT Toddlers supplemental safety study [5][6]. Net Loss - The company recorded a net loss of $69.0 million for the six months ended June 30, 2025, compared to a net loss of $60.5 million for the same period in 2024. The net loss per share was $(0.58) for the first half of 2025, compared to $(0.63) for the same period in 2024 [7][9]. Cash Position - Cash and cash equivalents amounted to $103.2 million as of June 30, 2025, a significant increase from $32.5 million as of December 31, 2024, reflecting a net increase of $70.7 million [10][14]. - The company announced a financing of up to $306.9 million to advance the Viaskin Peanut patch, with gross proceeds of $125.5 million received on April 7, 2025 [11][12]. Assets and Liabilities - As of June 30, 2025, total assets were $143.4 million, with liabilities of $57.2 million, resulting in shareholders' equity of $86.2 million [16].

Core Insights - DBV Technologies has appointed James Briggs as Chief Human Resources Officer, succeeding Caroline Daniere, to lead the company's transition from a development-stage biotechnology firm to a potential commercial organization [1][2] - James Briggs brings extensive experience in human capital strategy and organizational transformation, having previously served as a Partner at East Bay Human Capital and held executive roles at MNG Health, Ciox Health, and Ikaria Inc. [2] - The company is focused on developing treatment options for food allergies using its proprietary VIASKIN® patch technology, which aims to modify the immune response to allergens through epicutaneous immunotherapy [4] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company headquartered in Châtillon, France, with operations in North America [5] - The company is currently conducting clinical trials for its VIASKIN Peanut product aimed at peanut allergic toddlers and children [4] - DBV Technologies is committed to transforming the care of individuals with food allergies, addressing a significant unmet medical need [4]

Core Viewpoint - DBV Technologies has initiated the COMFORT Toddlers supplemental safety study for the Viaskin® Peanut patch, targeting peanut-allergic children aged 1 to 3 years, marking a significant step towards advancing this treatment option to market [1][3][4]. Group 1: Study Details - The COMFORT Toddlers study aims to enroll approximately 480 subjects across 80 to 90 study centers in the U.S., Canada, Australia, the UK, and Europe [2]. - The study is a Phase 3 double-blind, placebo-controlled safety trial designed to supplement safety and efficacy data from the completed Phase 3 EPITOPE study [3]. - The study duration is six months, followed by an optional 18-month open-label treatment phase, allowing for up to 24 months of active treatment for participants in the active group [3]. Group 2: Investigator Insights - Dr. Jeffrey Leflein, the Principal Investigator, expressed enthusiasm about the first subject being screened and highlighted the commitment to peanut-allergic children and their families [3]. - Dr. Julie Wang, Global Principal Investigator, noted the significant unmet need for this specific cohort, emphasizing the importance of the study [4]. - CEO Daniel Tassé stated that the data from this study will be crucial for a Biologics License Application (BLA) submission to the FDA, anticipated in the second half of 2026 [4]. Group 3: Company Background - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies, particularly through its proprietary Viaskin® patch technology [9]. - The company aims to address food allergies, which affect millions, including young children, by utilizing epicutaneous immunotherapy (EPIT™) to desensitize the immune system [9]. - DBV is committed to transforming the care of food-allergic individuals and is currently conducting clinical trials for the Viaskin Peanut patch in both toddlers and children [9].

Core Viewpoint - DBV Technologies has initiated the COMFORT Toddlers supplemental safety study for the Viaskin® Peanut patch, targeting peanut-allergic children aged 1 to 3 years, marking a significant step towards advancing this treatment option to market [1][3][4]. Group 1: Study Details - The COMFORT Toddlers study aims to enroll approximately 480 subjects across 80 to 90 study centers in the U.S., Canada, Australia, the UK, and Europe [2]. - The study is a Phase 3 double-blind, placebo-controlled safety trial designed to supplement safety and efficacy data from the completed Phase 3 EPITOPE study [3]. - The study duration is six months, followed by an optional 18-month open-label treatment phase, allowing for up to 24 months of active treatment for participants in the active group [3]. Group 2: Investigator Insights - Dr. Jeffrey Leflein, the Principal Investigator, expressed enthusiasm about the first subject being screened and highlighted the commitment to peanut-allergic children and their families [3][4]. - Julie Wang, Global Principal Investigator, noted the significant unmet need for this specific cohort, reinforcing the importance of the study [4]. Group 3: Regulatory and Future Plans - The data generated from the COMFORT Toddlers study is expected to support a Biologics License Application (BLA) submission to the FDA, anticipated in the second half of 2026 under the Accelerated Approval Pathway [4]. - The company is focused on advancing the development of the Viaskin Peanut patch, which aims to address food allergies through epicutaneous immunotherapy [9].